Skip to content
    Dimension logo

    Dimension

    New York, New York, United StatesFounded 2022

    Dimension is a multistage, research-oriented venture capital firm partnering with companies across the frontiers of science and compute. Founded in 2022 by Zavain Dar, Adam Goulburn, and Nan Li, it invests at the intersection of life sciences and technology, including AI-driven drug discovery, computational biology, and software infrastructure for biopharma.

    41% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (4 deals in the last 12 months vs 6 prior). Average disclosed round size is $130.3M (across 27 rounds with reported amounts).

    Find people at Dimension on Goldilocks AI

    Portfolio

    26

    Fund Size

    $500M

    Top Stage

    Series A

    Last 12 Mo

    4

    Team

    AG

    Adam Goulburn

    AG

    Alana Green

    AZ

    Amy Zhen

    AB

    Anna Bitton

    AB

    AnneMarie Bott

    NL

    Nan Li

    NN

    Nikhil Namburi

    RH

    Rami Hathwar

    ZD

    Zavain Dar

    MF

    Miguel Fernando Duenas

    Managing Partner / Chief Investment Officer

    EP

    Ernesto Padron

    Director, Direct Investments

    JF

    Jonathan Fischer

    Investment Analyst

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    32 investments
    CompanyRoundAmountDate
    LLanyon AIUnknown$10.6MAug 2026
    Congruence Therapeutics logoCongruence TherapeuticsSeries B$39.5MMar 2026
    Automata logoAutomataSeries C$45MJan 2026
    Earendil logoEarendilUnknown$787MJan 2026
    Newlimit logoNewlimitSeries C$435MJan 2026
    EEarendil LabsUnknown$787MJan 2026
    Chai Discovery logoChai DiscoverySeries B$130MDec 2025
    Five One Four logoFive One FourSeries A$17MSep 2025
    Convoke logoConvokeSeed$8.6MAug 2025
    Chai Discovery logoChai DiscoverySeries A—Aug 2025
    Stately Bio logoStately BioSeed$12MMay 2025
    Newlimit logoNewlimitSeries B$130MMay 2025
    Aspect Biosystems logoAspect BiosystemsSeries B$115MJan 2025
    Enveda Biosciences logoEnveda BiosciencesSeries D$150MJan 2025
    Stately Bio logoStately BioSeed$12MJan 2025
    Newlimit logoNewlimitSeries B$130MJan 2025
    Kimia Therapeutics logoKimia TherapeuticsSeries A$55MDec 2023
    UUtaite Co LtdUnknown—Oct 2023
    Automata logoAutomataSeries C$40MOct 2023
    Automata logoAutomataSeries B$40MOct 2023
    Lilz logoLilzSeries B$4.1MJun 2023
    Newlimit logoNewlimitSeries A—May 2023
    Kimia logoKimiaSeries A$55MJan 2023
    Cajal Neuroscience logoCajal NeuroscienceSeries A$96MJan 2022
    Cajal logoCajalSeries A$96MJan 2022
    Page 1 of 2

    Top Co-Investors

    Last updated: 20 October 2026